Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04522739 · ClinicalTrials.gov registry record · Phase 4
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Dementia
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
NCT04522739 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 25 participants.
The verdict
NCT04522739, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate whether a blood pressure medication, spironolactone, can be tolerated by older African American adults that have memory and thinking problems, also called mild cognitive impairment (MCI). This study will also investigate the effect of spironolactone on memory and thinking abilities as measured by performance on cognitive tests, which are tests that measure memory and thinking skills. Participants will take spironolactone or a placebo for one year and will have 4 to 5 study visits during the study period.
Interventions
- DRUG Placebo
- DRUG Spironolactone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-09-06 |
| Est. Completion | 2025-09-23 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04522739
The ClinicalTrials.gov registry entry for NCT04522739 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04522739 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04522739 about?
NCT04522739 is a clinical study titled "Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Dementia". The purpose of this study is to investigate whether a blood pressure medication, spironolactone, can be tolerated by older African American adults that have memory and thinking problems, also called mild cognitive impairment (MCI). This study will also investigate the effect of spironolactone on mem...
What is the current status of trial NCT04522739?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2022-09-06. Estimated completion is 2025-09-23.
What interventions are being tested in trial NCT04522739?
The interventions under investigation include: Placebo (DRUG), Spironolactone (DRUG).
Who is sponsoring clinical trial NCT04522739?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.